SENSUS HEALTHCARE, INC. (NASDAQ:SRTS) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On August 3, 2017, Sensus Healthcare, Inc. (the “Registrant”) announced via press release the Registrant’s financial results for the second quarter of 2017. A copy of the Registrant’s press release is included herein as Exhibit 99.1 and incorporated herein by reference.
The Registrant makes reference to certain non-GAAP financial information in the press release. A reconciliation of these non-GAAP financial measures and other financial information is provided in the press release incorporated herein.
The information furnished under Item 2.02 of this Current Report, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
99.1Press Release, dated August 3, 2017.
Sensus Healthcare, Inc. ExhibitEX-99.1 2 s107009_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Sensus Healthcare Reports Record Second Quarter Financial Results Revenue growth of 39% marks seventh consecutive quarter of double-digit year-over-year gains Conference call begins at 4:30 Eastern time today BOCA RATON,…To view the full exhibit click here
About SENSUS HEALTHCARE, INC. (NASDAQ:SRTS)
Sensus Healthcare, Inc., formerly Sensus Healthcare, LLC, is a manufacturer of superficial radiation therapy devices. The Company designs, manufactures and markets medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy. The superficial radiation therapy is an alternative to surgical basal cell carcinoma treatment and squamous cell carcinoma treatment. The Company’s product, the SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions, such as keloids. The SRT-100 treats primary lesions that would otherwise be difficult or require surgery involving sensitive areas of the head and neck regions, such as the fold in the nose, eyelids, lips, corner of the mouth and the lining of the ear.